Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
2006 1
2007 2
2008 2
2009 5
2010 7
2011 9
2012 7
2013 13
2014 26
2015 25
2016 30
2017 37
2018 48
2019 61
2020 77
2021 77
2022 93
2023 92
2024 36

Text availability

Article attribute

Article type

Publication date

Search Results

575 results

Results by year

Filters applied: . Clear all
Page 1
Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial.
Wang ZX, Cui C, Yao J, Zhang Y, Li M, Feng J, Yang S, Fan Y, Shi J, Zhang X, Shen L, Shu Y, Wang C, Dai T, Mao T, Chen L, Guo Z, Liu B, Pan H, Cang S, Jiang Y, Wang J, Ye M, Chen Z, Jiang D, Lin Q, Ren W, Wang J, Wu L, Xu Y, Miao Z, Sun M, Xie C, Liu Y, Wang Q, Zhao L, Li Q, Huang C, Jiang K, Yang K, Li D, Liu Y, Zhu Z, Chen R, Jia L, Li W, Liao W, Liu HX, Ma D, Ma J, Qin Y, Shi Z, Wei Q, Xiao K, Zhang Y, Zhang Y, Chen X, Dai G, He J, Li J, Li G, Liu Y, Liu Z, Yuan X, Zhang J, Fu Z, He Y, Ju F, Liu Z, Tang P, Wang T, Wang W, Zhang J, Luo X, Tang X, May R, Feng H, Yao S, Keegan P, Xu RH, Wang F. Wang ZX, et al. Cancer Cell. 2022 Mar 14;40(3):277-288.e3. doi: 10.1016/j.ccell.2022.02.007. Epub 2022 Mar 3. Cancer Cell. 2022. PMID: 35245446 Free article. Clinical Trial.
Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial.
Lu Z, Wang J, Shu Y, Liu L, Kong L, Yang L, Wang B, Sun G, Ji Y, Cao G, Liu H, Cui T, Li N, Qiu W, Li G, Hou X, Luo H, Xue L, Zhang Y, Yue W, Liu Z, Wang X, Gao S, Pan Y, Galais MP, Zaanan A, Ma Z, Li H, Wang Y, Shen L; ORIENT-15 study group. Lu Z, et al. BMJ. 2022 Apr 19;377:e068714. doi: 10.1136/bmj-2021-068714. BMJ. 2022. PMID: 35440464 Free PMC article. Clinical Trial.
Transferrin receptor 1 ablation in satellite cells impedes skeletal muscle regeneration through activation of ferroptosis.
Ding H, Chen S, Pan X, Dai X, Pan G, Li Z, Mai X, Tian Y, Zhang S, Liu B, Cao G, Yao Z, Yao X, Gao L, Yang L, Chen X, Sun J, Chen H, Han M, Yin Y, Xu G, Li H, Wu W, Chen Z, Lin J, Xiang L, Hu J, Lu Y, Zhu X, Xie L. Ding H, et al. J Cachexia Sarcopenia Muscle. 2021 Jun;12(3):746-768. doi: 10.1002/jcsm.12700. Epub 2021 May 6. J Cachexia Sarcopenia Muscle. 2021. PMID: 33955709 Free PMC article.
Nivolumab and relatlimab for the treatment of melanoma.
Chen XY, Li YD, Xie Y, Cao LQ, Ashby CR Jr, Zhao H, Chen ZS. Chen XY, et al. Drugs Today (Barc). 2023 Feb;59(2):91-104. doi: 10.1358/dot.2023.59.2.3509756. Drugs Today (Barc). 2023. PMID: 36811409 Review.
Gut microbiota bridges the iron homeostasis and host health.
Xiao L, Tang R, Wang J, Wan D, Yin Y, Xie L. Xiao L, et al. Sci China Life Sci. 2023 Sep;66(9):1952-1975. doi: 10.1007/s11427-022-2302-5. Epub 2023 Jul 27. Sci China Life Sci. 2023. PMID: 37515687 Review.
575 results